- Sector
- Healthcare
- Industry
- Biotechnology
- IPO Date
- May 12, 2015
Highlights
- EPS (TTM)
- -$10.44
- Total Revenue (TTM)
- $1.31M
- Gross Profit (TTM)
- -$2.65M
- EBITDA (TTM)
- -$6.53M
- Year Range
- $0.29 - $3.48
- ROA (TTM)
- -71.45%
- ROE (TTM)
- -102.52%
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
SCNI Performance Chart
Scinai Immunotherapeutics Ltd (SCNI) is down 59.1% since the beginning of the year. At $0 per share, SCNI is trading 91.6% below its 52-week high of $3. Investors who bought $1,000 worth of SCNI shares 5 years ago would now be looking at an investment worth $1.
Loading charts...
Returns By Period
Scinai Immunotherapeutics Ltd (SCNI) has returned -59.13% so far this year and -86.86% over the past 12 months. Over the last ten years, SCNI has returned -51.32% per year, falling short of the S&P 500 Index benchmark, which averaged 13.88% annually.
Scinai Immunotherapeutics Ltd
- 1D
- -9.49%
- 1M
- -36.90%
- YTD
- -59.13%
- 6M
- -63.42%
- 1Y
- -86.86%
- 3Y*
- -72.10%
- 5Y*
- -74.98%
- 10Y*
- -51.32%
Benchmark (S&P 500 Index)
- 1D
- -0.37%
- 1M
- -0.01%
- YTD
- 9.16%
- 6M
- 8.64%
- 1Y
- 25.22%
- 3Y*
- 19.78%
- 5Y*
- 11.99%
- 10Y*
- 13.88%
SCNI Monthly Returns History
Based on dividend-adjusted daily data since May 12, 2015, SCNI's average daily return is -0.06%, while the average monthly return is -1.86%.
Historically, 41% of months were positive and 59% were negative. The best month was Apr 2020 with a return of +75.3%, while the worst month was Oct 2020 at -92.3%. The longest winning streak lasted 6 consecutive months, and the longest losing streak was 8 months.
On a daily basis, SCNI closed higher 42% of trading days. The best single day was Dec 22, 2021 with a return of +97.3%, while the worst single day was Oct 23, 2020 at -86.3%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 37.62% | -9.33% | -35.85% | 29.82% | -39.19% | -35.33% | -59.13% | ||||||
| 2025 | 7.29% | -1.36% | -23.90% | -2.06% | 3.09% | -16.18% | -35.96% | 4.79% | -17.32% | 10.67% | -26.43% | -30.86% | -78.71% |
| 2024 | -20.98% | 4.34% | 5.72% | -12.31% | -17.60% | -25.86% | 67.63% | -19.96% | -7.51% | 3.19% | -3.37% | -2.76% | -43.82% |
| 2023 | -11.82% | -9.77% | -8.28% | -10.65% | -8.29% | -20.34% | -5.67% | 1.50% | -35.56% | -24.14% | 8.94% | -17.19% | -79.89% |
| 2022 | -44.26% | -3.05% | 30.71% | -22.29% | 3.88% | -13.06% | 2.58% | -7.53% | -33.94% | 3.99% | 28.57% | -69.67% | -87.40% |
| 2021 | 61.92% | -12.53% | -4.52% | -15.79% | -5.31% | -5.28% | 1.74% | -7.88% | -18.22% | -5.45% | -17.31% | 36.63% | -16.37% |
Benchmark Metrics
Scinai Immunotherapeutics Ltd has an annualized alpha of -23.99%, beta of 0.87, and R2 of 0.03 versus S&P 500 Index. Calculated based on daily prices since May 12, 2015.
- This stock participated in 244.83% of S&P 500 Index downside but only 31.31% of its upside - more exposed to losses than it benefited from rallies.
- R2 of 0.03 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- -23.99%
- Beta
- 0.87
- R²
- 0.03
- Upside Capture
- 31.31%
- Downside Capture
- 244.83%
Return for Risk
Risk / Return Rank
SCNI ranks 6 for risk / return — in the bottom 6% of stocks on our site. This means you're taking on significantly more risk than the returns justify. Consider whether the potential upside is worth the volatility, or explore alternatives with better risk / return profiles.
Return / Risk — by metrics
The table below present risk-adjusted performance metrics for Scinai Immunotherapeutics Ltd (SCNI) and compare them to S&P 500 Index.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| SCNI | Benchmark | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -2.77 | ||
| Sortino ratioReturn per unit of downside risk | -4.61 | ||
| Omega ratioGain probability vs. loss probability | 0.80 | 1.37 | -0.57 |
| Calmar ratioReturn relative to maximum drawdown | -0.98 | 2.78 | -3.77 |
| Martin ratioReturn relative to average drawdown | -1.44 | 12.44 | -13.88 |
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the Scinai Immunotherapeutics Ltd. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Scinai Immunotherapeutics Ltd was 99.99%, occurring on Jun 22, 2026. The portfolio has not yet recovered.
The current Scinai Immunotherapeutics Ltd drawdown is 99.99%.
Related event | Drawdown | Fall | Recovery | Underwater |
|---|---|---|---|---|
2026 bear market2026 | -99.99%Jun 2026 | 5y 11mo | — | 5y 11moJul 2020 - now |
Rate-hike selloffLate 2018 | -61.86%Dec 2018 | 1y 5mo | 1y 20d | 2y 5moJul 2017 - Jan 2020 |
COVID crash2020 | -53.99%Mar 2020 | 1mo 16d | 1mo 14d | 3moJan 2020 - Apr 2020 |
2016 bear market2016 | -39.76%Nov 2016 | 1y 4mo | 2mo 18d | 1y 7moJun 2015 - Feb 2017 |
2020 bear market2020 | -26.79%Jun 2020 | 20d | 12d | 1mo 2dMay 2020 - Jun 2020 |
Drawdown Indicators
| SCNI | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -99.99% | -56.78% | -43.21% |
Max Drawdown (1Y)Largest decline over 1 year | -88.45% | -9.10% | -79.35% |
Max Drawdown (3Y)Largest decline over 3 years | -98.17% | -18.90% | -79.27% |
Max Drawdown (5Y)Largest decline over 5 years | -99.92% | -25.43% | -74.49% |
Max Drawdown (10Y)Largest decline over 10 years | -99.99% | -33.92% | -66.07% |
Current DrawdownCurrent decline from peak | -99.99% | -1.80% | -98.19% |
Average DrawdownAverage peak-to-trough decline | -65.01% | -10.71% | -54.30% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 60.12% | 2.03% | +58.09% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Scinai Immunotherapeutics Ltd over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how Scinai Immunotherapeutics Ltd is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for SCNI relative to other companies in the Biotechnology industry. Currently, SCNI has a P/S ratio of 0.2. This P/S ratio is low compared to the industry average. It may indicate that the stock is undervalued relative to its revenue, or that the market expects slower growth or lower margins.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with SCNI
Add Scinai Immunotherapeutics Ltd to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with SCNI